A stromal cell niche sustains ILC2-mediated type-2 conditioning in adipose tissue

Group-2 innate lymphoid cells (ILC2), type-2 cytokines, and eosinophils have all been implicated in sustaining adipose tissue homeostasis. However, the interplay between the stroma and adipose-resident immune cells is less well understood. We identify that white adipose tissue-resident multipotent s...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 216; no. 9; pp. 1999 - 2009
Main Authors Rana, Batika M J, Jou, Eric, Barlow, Jillian L, Rodriguez-Rodriguez, Noe, Walker, Jennifer A, Knox, Claire, Jolin, Helen E, Hardman, Clare S, Sivasubramaniam, Meera, Szeto, Aydan, Cohen, E Suzanne, Scott, Ian C, Sleeman, Matthew A, Chidomere, Chiamaka I, Cruz Migoni, Sara, Caamano, Jorge, Jorgensen, Helle F, Carobbio, Stefania, Vidal-Puig, Antonio, McKenzie, Andrew N J
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 02.09.2019
Subjects
Adipose Tissue, White - cytology
Animals
Cell Proliferation
Eosinophils - metabolism
Immunity, Innate
Interleukin-33
Interleukin-5 - biosynthesis
Lymphocytes - cytology
Lymphocytes - immunology
Mice, Inbred BALB C
Mice, Inbred C57BL
Stromal Cells - cytology
Online AccessGet full text

Cover

More Information
Summary:Group-2 innate lymphoid cells (ILC2), type-2 cytokines, and eosinophils have all been implicated in sustaining adipose tissue homeostasis. However, the interplay between the stroma and adipose-resident immune cells is less well understood. We identify that white adipose tissue-resident multipotent stromal cells (WAT-MSCs) can act as a reservoir for IL-33, especially after cell stress, but also provide additional signals for sustaining ILC2. Indeed, we demonstrate that WAT-MSCs also support ICAM-1-mediated proliferation and activation of LFA-1-expressing ILC2s. Consequently, ILC2-derived IL-4 and IL-13 feed back to induce eotaxin secretion from WAT-MSCs, supporting eosinophil recruitment. Thus, MSCs provide a niche for multifaceted dialogue with ILC2 to sustain a type-2 immune environment in WAT.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
M.A. Sleeman’s present address is Regeneron Pharmaceuticals, Tarrytown, NY.
C.S. Hardman’s present address is Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, National Institute for Health Research Biomedical Research Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20190689